Breast Cancer Recurrence Fear & Emotional Impact: New Study Findings

For women diagnosed with early-stage, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the fear of recurrence is a dominant concern. A new study, ‘ImpOrta. Experiencia asistencial e impacto del cáncer de mama precoz desde la perspectiva de las pacientes,’ reveals that 84 percent of patients grapple with this anxiety, followed by uncertainty about the disease’s future course (72%) and apprehension about long-term side effects (57%).

The Weight of Uncertainty

The study, conducted in Spain, surveyed 131 women undergoing treatment following surgery for this specific subtype of breast cancer. Researchers found that avoiding open discussion about the possibility of recurrence doesn’t alleviate fear; instead, it often amplifies uncertainty, a key source of distress for patients. Laura Bascuñana, a nursing supervisor at Hospital Vall d’Hebron and a representative of the Sociedad Española de Enfermería Oncológica (SEEO), emphasized the importance of normalizing these conversations, using clear and realistic language tailored to each individual.

A Significant Health Challenge

Breast cancer remains a major health concern in Spain, with an estimated 516,827 people currently living with the disease. More than 38,000 new cases are diagnosed annually, resulting in over 6,000 deaths, making it a leading cause of cancer-related mortality among women. The HR+/HER2- subtype accounts for approximately 70 percent of all breast cancer diagnoses, with 90 percent identified in non-metastatic stages.

Beyond Surgery: The Long Road of Treatment

Despite advancements in treatment, the study highlights that two out of three patients diagnosed with early-stage HR+/HER2- breast cancer in stages II and III face a long-term risk of recurrence – ranging from 5 to 20 years – which can manifest as incurable advanced disease. This recurrence carries a substantial clinical and emotional burden for patients and their families, and also impacts healthcare systems.

The ‘ImpOrta’ study also reveals that treatment doesn’t necessarily end with surgery. Many patients receive years of adjuvant therapy – administered after surgery to eliminate remaining cancer cells and reduce recurrence risk – which can bring its own set of symptoms and side effects, potentially affecting adherence and quality of life.

Emotional Toll and Common Symptoms

The emotional impact of a breast cancer diagnosis is profound. An overwhelming 95 percent of patients experience worry, anguish, or fear, while 93 percent report feelings of insecurity or uncertainty, and 90 percent experience sadness. However, patients also frequently report feelings of support and reassurance (95%).

These emotions evolve throughout the treatment process. Negative emotions are more prevalent during diagnosis, reflecting the shock of the news. As patients progress through surgery and adjuvant therapies, feelings of exhaustion increase (from 36% to 64%), but are often accompanied by positive emotions like a sense of security (34% to 52%), confidence (24% to 56%), and relief (11% to 37%).

Common physical symptoms reported by patients include muscle and joint pain (80%), fatigue (68%), sleep problems (57%), and difficulties with memory or concentration (47.5%). Other reported symptoms include mood changes (33%), hot flashes (31%), gastrointestinal issues (25%), hair loss (25%), sexual problems (24%), and skin problems (22%).

Information Gaps and the Need for Empowerment

While 72.5 percent of participants believe patients receive information about adjuvant treatments, over half (54%) feel they are not adequately informed about the risk of recurrence, and 16 percent are unsure. This discrepancy may stem from the complexity of the information, how it’s delivered, or the emotional state of patients during this challenging time.

The study emphasizes the importance of empowering patients with clear, understandable information about their condition, the risk of recurrence, and how to manage treatment side effects. This knowledge can enable active participation in their care, reduce uncertainty, and improve long-term adherence and quality of life, particularly given the years of follow-up care often required.

Frequently Asked Questions

What is the most common concern for patients with early-stage HR+/HER2- breast cancer?

The primary concern is the fear of the cancer returning, reported by 84 percent of patients in the study.

What percentage of patients experience negative emotions like worry or fear?

An overwhelming 95 percent of patients experience worry, anguish, or fear.

What are some of the most common physical symptoms experienced by patients?

The most frequently reported physical symptoms are muscle and/or joint pain (80%) and fatigue (68%).

How might a more open dialogue between patients and healthcare providers impact the experience of living with early-stage breast cancer?